Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 09/08

20080234464 - Compound having amino acid residue or peptide residue and process for producing the same: P

20080234466 - Delivery method for the tumor-specific apoptosis-inducing activity of apoptin: The invention relates to the field of apoptosis. The invention provides novel therapeutic substances, for example, novel therapeutic proteinaceous compounds that can contain apoptin alone or jointly with other proteinaceous protein or protein fragments, especially in those cases when cells are derailed such as cancer-, autoimmune-derived cells.... Agent: Trask Britt

20080234465 - Expression in filamentous fungi of protease inhibitors and variants thereof: Described herein are protease inhibitors, variants thereof and methods for their production.... Agent: Genencor International, Inc. Attention: Legal Department

20080234467 - Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis: The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage including a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) covalently bound to X.... Agent: Clark & Elbing LLP

20080234468 - Novel 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules,... Agent: Millennium Pharmaceuticals, Inc.

20080234469 - Tumour necrosis factor binding ligands: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of... Agent: Morrison & Foerster LLP

20080234470 - Kcnb: a novel potassium channel protein: The present invention provides nucleic acid and protein sequences for a novel potassium channel protein, KCNB. The herein-disclosed sequences can be used for any of a number of purposes, including for the specific detection of KCNB, for the identification of molecules that associate with and/or modulate the activity of KCNB,... Agent: Banner & Witcoff, Ltd.

20080234471 - Fucosyl transferase gene: A DNA molecule is provided which comprises a sequence according to SEQ ID NO: 1 having an open reading frame from base pair 211 to base pair 1740 or having at least 50% homology to the above-indicated sequence, or hybridizing with the above-indicated sequence under stringent conditions, or comprising a... Agent: Buchanan, Ingersoll & Rooney PC

20080227953 - C-mpl ligand polypeptide: A meg-CSF/thrombopoietin-like protein that is present in plasma of irradiated pigs has been purified. This protein, the porcine Mpl ligand polypeptide (ML), binds to and activates the c-Mpl receptor protein, a member of the cytokine receptor superfamily. The isolated Mpl ligand stimulates both megakaryocytopoiesis and thrombopoiesis.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080227955 - Nematode pan and zp receptor-like sequences: Nucleic acid molecules from nematodes encoding PAN and ZP domain containing receptor polypeptides are described. PANZP polypeptide sequences are also provided, as are vectors, host cells, and recombinant methods for production of PANZP nucleotides and polypeptides. Also described are screening methods for identifying inhibitors and/or activators, as well as methods... Agent: Fish & Richardson PC

20080227954 - Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis: The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage including a pharmacologically active peptide sequence (X) and a stabilising petide sequence (Z) covalently bound to X.... Agent: Clark & Elbing LLP

20080227956 - Novel morphogenic protein compositions of matter: Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)

20080227957 - Reducing immunogenicities of immunoglobulins by framework-patching: Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described methods of humanization, which graft CDRs from a donor onto the frameworks of a single acceptor immunoglobulin, we patch segments of framework (FR1, FR2, FR3, and FR4),... Agent: Smith Patent Consulting Consulting, LLC

20080227958 - Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions: Provided herein are binding proteins comprising one or more immunoglobulin Fc region hinge, CH2, and/or CH3 domain wherein one or more hinge and/or constant region CH2 and/or CH3 domain is modified to alter the binding protein's binding affinity and/or specificity for a cognate receptor (e.g., an Fc receptor) and/or to... Agent: Darby & Darby P.C.

20080227959 - Reagents for detecting efavirenz: The invention provides derivatives of efavirenz and methods of making derivatives of efavirenz. The derivatives include immunogenic compounds for producing antibodies to efavirenz and labeled efavirenz tracers. These compounds are useful in immunoassay methods for determining efavirenz.... Agent: Roche Diagnostics Operations Inc.

20080227960 - Crystal structure of estrogen receptor-beta complex and uses thereof: This invention is directed to the crystal structure of Estrogen Receptor-β (ER-β) complexed with genistein, and to the use of this structure in rational drug design methods to identify agents that may interact with active sites of ER-β, which may be useful as novel chemotherapeutic agents.... Agent: Lowrie, Lando & Anastasi, LLP W2023

20080221303 - Method for the preparation of peptide-oligonucleotide conjugates: The present invention relates to the synthesis of peptide-oligonucleotide conjugates (POC). More specifically, the invention relates to a novel method for the preparation of peptide-oligonucleotide conjugates, which can be conducted under mild conditions on solid support, can be performed manually or by a synthesizer, can be used to synthesize alternating... Agent: Winston & Strawn LLP Patent Department

20080221304 - Nociceptin-based analgesics: The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds... Agent: Kirton & Mcconkie

20080221305 - Polynucleotides encoding novel adiponectin receptor variants: The present invention provides novel polynucleotides encoding human AdipoR2v1 polypeptides, mouse AdipoR2v1 polypeptides, human AdipoR3 polypeptides, human AdipoR2v2 polypeptides, human AdipoR3v1 polypeptides, rat AdipoR1 polypeptides, rat AdipoR2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention... Agent: Louis J. Wille Bristol-myers Squibb Company

20080221307 - Neutralizing determinants of il-17 receptor a and antibodies that bind thereto: The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and the antigen binding proteins, such as antibodies, that bind thereto and inhibit IL-17 ligand family members from binding to and activating IL-17 Receptor A or a receptor complex comprising IL-17 Receptor A.... Agent: Amgen Inc. Law Department

20080221306 - Humanized antibodies that recognize beta amyloid peptide: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.... Agent: Townsend And Townsend And Crew, LLP

20080221308 - Hdac9 polypeptides and polynucleotides and uses thereof: The present invention features substantially pure HDAC9, HDAC9a, HDAC9(ΔNLS), HDAC9a(ΔNLS), an HDRP(ΔNLS) polypeptides, and isolated nucleic acid molecules encoding those polypeptides. The present invention also features vectors containing HDAC9, HDAC9a, HDAC9(ΔNLS), HDAC9a(ΔNLS), and HDRP(ΔNLS) nucleic acid sequences, and cells containing those vectors.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c.

20080221309 - Mn gene and protein: A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in... Agent: Leona L. Lauder

20080221310 - Extraction of cellular components with fatty acid derivatives: A method of treating biologic material with a composition containing at least one fatty acid derivative and/or at least one fatty alcohol, a buffer, and a salt to result in protein partitioning into an aqueous phase and an organic phase. The protein may be a membrane protein. The cells may... Agent: Thompson Hine L.l.p. Intellectual Property Group

20080221311 - Preparation method of insect cell extract solution for cell-free protein synthesis, the insect cell extract solution and cell-free synthesis method of protein using the insect cell extract solution: The present invention provides a preparation method of an insect cell extract solution for cell-free protein synthesis, the insect cell extract solution, a protein synthesis method in a cell-free system, which uses the insect cell extract solution, and a kit for cell-free protein synthesis containing the insect cell extract solution.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080214781 - Leucine-based motif and clostridial neurotoxins: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods... Agent: Allergan, Inc.

20080214782 - Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides: The present invention relates to phosphopeptide compositions and anti-phosphopeptide antibody compositions. Also provided are methods of identifying phosphorylation sites in phosphorylated peptides and phosphorylation site motifs.... Agent: Lawson & Weitzen, LLP

20080214783 - Method of synthesizing protein, mrna immobilized on solid phase and apparatus for synthesizing protein: The present invention provides a protein synthesis method for efficiently synthesizing a desired protein so that it is properly folded so as to demonstrate a function thereof, the method comprising contacting a translation system with a solid phase-immobilized mRNA in which mRNA encoding that protein is immobilized on a solid... Agent: Foley And Lardner LLP Suite 500

20080214784 - Human t1r2 taste receptor polypeptides: Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors.... Agent: Hunton & Williams LLP Intellectual Property Department

20080214785 - Human cytokine receptor: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20080214786 - Modified powder, fluid composition containing said modified powder, formed article, and method for producing modified powder: The modifying powder is silk powder having an average particle diameter of 10 μm or less, oil absorption of 130 ml/100 g or less and particle diameter of 80 μm or less on the basis of dispersion degree evaluation with a grind gauge according to JIS K5400; or polysaccharide powder... Agent: Millen, White, Zelano & Branigan, P.C.

20080214789 - Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy: The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such antagonists to treat autoimmune disease in a patient who has failed prior treatment such as treatment with DMARDs or TNFα-inhibitors.... Agent: Heller Ehrman LLP

20080214788 - Interferon-like protein zcyto21: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20080214787 - Mn gene and protein: A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in... Agent: Leona L. Lauder

20080214790 - Leafthopper ecdysone receptor nucleic acids, polypeptides, and uses thereof: The present invention relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation... Agent: Intrexon Corporation

20080214791 - Monoclonal antibodies to human high molecular weight-melanoma associated antigen: The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.... Agent: Darby & Darby P.C.

20080214793 - Method for extracting a biosubstance from hair and hair sampling device useful in the method: Disclosed herein is a method for extracting a biosubstance from a root of a hair, including the step of using as the hair a hair that has pulling force of at least a predetermined reference value to pull out the hair.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080214792 - Systems and methods for separating proteins from connective tissue: Methods and systems for separating muscle tissue from connective tissue are provided, in which animal tissue containing both muscle tissue and connective tissue is subjected to stress, and muscle proteins are separated from the connective tissue. Slurries of separated myofibrillar protein are also provided.... Agent: Burns & Levinson, LLP

20080214794 - Method and device for extracting an analyte: The invention provides columns and methods for the purification and concentration of an analyte (e.g., a biological macromolecule, such as a peptide, protein or nucleic acid) from a sample solution. The columns typically include a bed of extraction medium positioned in the column between two frits. In some embodiments, the... Agent: Phynexus, Inc.

20080214795 - Method of isolating antibodies by precipitation: Methods of isolating antibodies by precipitation are disclosed. Various precipitants that can be employed in the invention are also disclosed, with PEG being a preferred precipitant. In a representative embodiment of the invention, the pH of a solution comprising an antibody of interest is adjusted to ±0.5 pH unit of... Agent: Amgen Inc.

20080214796 - Method: A method for controlling the sodium and sulphur balance of a pulp mill while separating lignin from black liquor, and also a lignin product or an intermediate lignin product obtainable by the method. The present invention also provides use of a lignin product or an intermediate lignin product for the... Agent: Young & Thompson